LexBlog IP

AUGUST 30, 2023

It has been reported that Celltrion has finalized a settlement with Johnson & Johnson (“J&J”) in the United States relating to CT-P43, Celltrion’s ustekinumab biosimilar to J&J’s STELARA®, which would permit Celltrion to launch the product in the U.S. market on March 7, 2025, if approved by FDA.

Settlement 52

Settlement Confidentiality Marketing Marketing 52

LexBlog IP

AUGUST 16, 2023

On August 7, 2023, Formycon AG and Fresenius Kabi announced that they have reached a settlement with Johnson & Johnson (“J&J”) in the United States relating to FYB202, a proposed ustekinumab biosimilar to STELARA®, marketed by J&J. Economic terms of the settlement were not disclosed in the press release.

Settlement 52

Settlement Licensing Confidentiality Marketing 52

Bio Law Blog

JUNE 21, 2020

On May 28, Alexion and Amgen entered into a confidential settlement agreement to terminate the IPRs. Pursuant to the terms of the settlement agreement, effective March 1, 2025 (or earlier in certain circumstances), Alexion grants to Amgen a nonexclusive, royalty-free license under U.S. an eculizumab product.

Marketing 52

Marketing Marketing Settlement Patent 52

Fish & Richardson Trademark & Copyright Thoughts

FEBRUARY 4, 2021

No earlier than July 31, 2023 per settlement. No earlier than November 20, 2023 per settlement. . No earlier than June 30, 2023 per settlement. No earlier than September 30, 2023 per settlement. No earlier than July 1, 2023 per settlement. No earlier than January 31, 2023 per settlement. January 2021.

Litigation 52

Litigation Settlement Marketing Marketing 52